Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
diffuse midline gliomamedical
An aggressive, hard-to-treat brain tumor that grows in the central parts of the brain or spinal cord, often disrupting critical functions like movement and speech much like a weed taking root in the engine of a machine. It matters to investors because its severity and limited treatment options create high unmet medical need, which can drive the value of research programs, regulatory incentives, drug pricing and the commercial prospects of therapies in development.
H3 K27M mutationmedical
A H3 K27M mutation is a single, specific change in a protein that helps package DNA in cells, where the amino acid lysine (K) at position 27 is replaced by methionine (M). That small change can profoundly alter gene control in certain aggressive brain tumors, influencing prognosis, eligibility for targeted treatments and clinical trials, and thus potential regulatory approvals, market value of therapies, and investment risk in related biotech stocks.
Phase IImedical
Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
STAMFORD, Conn.--(BUSINESS WIRE)--
HealthCare Royalty (“HCRx”) today announced it has entered into a royalty monetization agreement with the Advisory Group representing the former Oncoceutics Inc. securityholders for an undisclosed percentage of royalties on Modeyso® (dordaviprone) commercial sales.
Modeyso received U.S. FDA accelerated approval in August 2025 for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso is commercialized by Jazz Pharmaceuticals.
“Since its launch in August, Modeyso has demonstrated strong early performance, reflecting the significant unmet need, high awareness driven by advocacy groups, and the value physicians see for patients with H3 K27M-mutant diffuse midline glioma,” said Clarke Futch, Chairman and Chief Executive Officer of HealthCare Royalty. “We believe Modeyso is uniquely positioned to bring meaningful benefit to patients who previously had no approved treatment options, and we are pleased to add this important therapy to HCRx’s growing portfolio.”
“On behalf of all of the former shareholders of Oncoceutics, we are pleased that HCRx shares our belief that Modeyso can create significant value as a new treatment option for patients with H3 K27M-mutant diffuse midline glioma,” said Lee Schalop, co-founder and former CEO of Oncoceutics, which took the molecule ONC201 that became Modeyso from its discovery through Phase II efficacy data.
About HEALTHCARE ROYALTY
HealthCare Royalty (“HCRx”) is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing $7+ billion in over 110 biopharmaceutical products. With offices in New York, Stamford, San Francisco, Boston, London and Miami, HCRx continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties. For more information, visit https://www.hcrx.com. HEALTHCARE ROYALTY®, HEALTHCARE ROYALTY PARTNERS® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC.
Modeyso is a registered trademark of Jazz Pharmaceuticals Inc.
